Literature DB >> 11712286

Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose.

R A O'Reilly1, P M Aggeler.   

Abstract

Thirty normal subjects were given a single loading dose of warfarin sodium, 1.5 mg/kg of body weight. The drug was metabolized slowly (mean biological half-life, 47 hr) and showed a prolonged biological effect (over 6 days). In two separate experiments no loading dose was given; instead, daily doses of 15 mg and 10 mg were administered to 15 of the subjects. The prothrombin complex responses were compared with those obtained in the same subjects after the large loading dose. The mean time in days to reach the therapeutic range (prothrombin complex activity < 35% of normal) was 1.1 days with the dose of 1.5 mg/kg of body weight, 2.7 days with the dose of 15 mg/day, and 5.2 days with 10 mg/day. With all three methods the therapeutic range was reached soon after a level of warfarin of 2 mg/L plasma was attained. The rates of fall of the four vitamin K-dependent clotting factors (II, VII, IX, and X) with the large loading dose and with the daily dosage of 15 mg were compared in six of the subjects. With the loading dose, factor VII activity was less during the first 48 hr, but there was no other significant difference between the two methods of drug administration in the amount of reduction of any of the four factors. Since the role of factor VII in thrombogenesis is questioned, these results provide a rational basis for the induction of prophylactic anticoagulant therapy without large loading doses of warfarin. Avoidance of the customary loading dose should reduce the danger of hemorrhage, particularly in patients who are sensitive to the drug because of advanced age, sepsis, liver disease, congestive heart failure, or recent surgery or trauma.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 11712286     DOI: 10.1161/01.cir.38.1.169

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.

Authors:  J M Walenga; D Hoppensteadt; R Pifarré; N L Fox; S Forman; D B Hunninghake; L Campeau; J A Herd; B J Hoogwerf; A Hickey; J L Probstfield; M L Terrin
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

3.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

4.  Visual Predictive Check in Models with Time-Varying Input Function.

Authors:  Anna Largajolli; Alessandra Bertoldo; Marco Campioni; Claudio Cobelli
Journal:  AAPS J       Date:  2015-08-12       Impact factor: 4.009

5.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

6.  A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.

Authors:  Qing Xi Ooi; Daniel F B Wright; R Campbell Tait; Geoffrey K Isbister; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 7.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

8.  Drug concentration, binding, and effect in vivo.

Authors:  N H Holford
Journal:  Pharm Res       Date:  1984-05       Impact factor: 4.200

Review 9.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

10.  Novel anticoagulants in atrial fibrillation stroke prevention.

Authors:  Nicholas B Norgard; James J Dinicolantonio; Taylor J Topping; Benjamin Wee
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.